Skip to main content

Advertisement

SpringerLink
Log in

C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The advent of anti-tumour necrosis factor (TNF) agents to treat inflammatory arthritis has dramatically changed the management of patients in the last few years. Other possible indications for these agents are currently being explored in preliminary studies. However, whether this therapy can be safely and efficaciously applied to other inflammatory disorders requires further case-controlled studies. Since these agents are increasingly used in the last 7 years, there has been the expected emergence of reports on uncommon side effects. The literature on the side effects of anti-TNF agents has focused on infective complications and development of autoantibodies. Reports concerning vasculitis have been contradictory, with TNF blockade being implicated in both the development and treatment of vasculitis. We present the first published report of necrotising crescentic glomerulonephritis associated with positive antineutrophil cytoplasmic antibody in a man receiving treatment with infliximab for rheumatoid arthritis. We discuss the literature and potential causal mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P (2003) Anti-tumour necrosis factor-α therapy induced vasculitis. J Rheumatol 30:102287–102292

    Google Scholar 

  2. Eriksson C, Engstrand S, Sundqvist K-G, Rantapaa-Dahlqvist S (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Ann Rheum Dis 64:403–407

    Article  PubMed  CAS  Google Scholar 

  3. Schönermarck U, Lamprecht P, Csernok E, Gross WL (2001) Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. Rheumatology 40:178–184

    Article  PubMed  Google Scholar 

  4. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL (1997) Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 126:866–873

    PubMed  CAS  Google Scholar 

  5. Little MA, Bhangal G, Smyth CL, Nakata MT, Cook HT, Noursharg S, Pusey CD (2006) Therapeutic effect of anti-TNF alpha antibodies in an experimental model of anti-neutrophil cytoplasm associated systemic vasculitis. J Am Soc Nephrol 17(1):160–169

    Article  PubMed  CAS  Google Scholar 

  6. Booth AD, Jayne DTW, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, Wilkinson IB (2004) Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 109:1718–1723

    Article  PubMed  CAS  Google Scholar 

  7. Louis M, Rauch J, Armstrong M, Fitzcharles MN (2003) Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 30:2557–2562

    PubMed  CAS  Google Scholar 

  8. Douglas E, Bird K, Flume P, Silver R, Bolster M (2003) Wegener’s granulomatosis in patients with rheumatoid arthritis. J Rheumatol 30:9

    Google Scholar 

  9. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, Moore B, Wolde D, D’Agati VD (2005) Development of glomerulonephritis during anti-TNF -therapy for rheumatoid arthritis. Nephrol Dial Transplant 20:1400–1406

    Article  PubMed  CAS  Google Scholar 

  10. D’Cruz D, Chesser AMS, Lightowler C, Comer M, Hurst J, Baker LRI, Raine AEG (1995) Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Rheum 34:1090–1091

    Article  CAS  Google Scholar 

  11. D’Agati VD (1998) Renal disease in systemic lupus erythematosus mixed connective tissue disease, Sjogrens’s syndrome, and rheumatoid arthritis. In: Jennette JC, Oslen JL, Schwartz MM et al (eds) Heptinstall’s pathology of the kidney, vol 1. Lippincott-Raven, PA, pp 541–624

  12. Gaffey CM, Chun B, Harvey JC, Manz HJ (1986) Phenytoin-induced systemic granulomatous vasculitis. Arch Pathol Lab Med 110(2):131–135 (Feb)

    PubMed  CAS  Google Scholar 

  13. Cuchacovich R, Espinoza LR (2002) Soluble TNF receptor treatment does not affect raised TGF beta levels in RA. Ann Rheum Dis 61:667

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Buckinghamshire Hospitals NHS Trust, Queen Alexandra Road, High Wycombe, Bucks, HP11 2TT, UK

    Dayavathi Ashok

  2. Department of Rheumatology, The Ipswich Hospital NHS Trust, Heath Road, Ipswich, Suffolk, IP4 5PD, UK

    Shirish Dubey

  3. Department of Rheumatology, Hull and East Yorkshire Hospitals NHS Trust, Anlaby Road, Kingston Upon Hull, HU3 2JZ, UK

    Ian Tomlinson

Authors
  1. Dayavathi Ashok
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shirish Dubey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian Tomlinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dayavathi Ashok.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ashok, D., Dubey, S. & Tomlinson, I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin Rheumatol 27, 261–264 (2008). https://doi.org/10.1007/s10067-007-0712-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-007-0712-0

Keywords

Search

Navigation